Skip to main content
SpringerLink
Log in

New microtubular agents in pediatric oncology

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The taxanes are a new group of anticancer agents with a novel mechanism of action. They promote microtubule assembly and stabilize the microtubules. Paclitaxel (Taxol), the first agent in this group in clinical trials was isolated from the Pacific yew, Taxus brevifolia in 1971. Both in preclinical and clinical studies, paclitaxel and its semisynthetic analog docetaxel exhibit significant antitumor activity. This review will provide an overview of the clinical experience with the group of anti-microtubular agents, the taxanes in pediatric oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wani MC, Taylor HL, Wall ME, Coggan P, McPhail AT: Plantantitumor agents VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus breviofolia. J Am Chem Soc 93:2325–2327, 1971.

    Google Scholar 

  2. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665–667, 1979.

    Google Scholar 

  3. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561–1565, 1980.

    Google Scholar 

  4. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247–1259, 1990.

    Google Scholar 

  5. Colin M, Guenard D, Gueritte-Voegelein F, et al.: Taxol derivatives, their preparation and pharmaceutical compositions containing them. Rhone-Poulenc Sante, US Patent 4814470, granted March 21, 1989 (priority date, July 17, 1986).

  6. Colin M, Guenard D, Gueritte-Voegelein F, et al.: Process for the preparation of Taxol and 10-deacetytaxol. Rhone-Poulenc Sante, US Patent 4857653, granted August 15, 1989 (priority date, July 17, 1986).

  7. Lavelle F, Fizames C, Gueritte-Voegelein F, et al.: Experimental properties of RP56976 a Taxol derivative. Proc Am Assoc Cancer Res 30:566, 1989 (abstract 2254).

    Google Scholar 

  8. Ringel I, Horwitz SB: Studies with RP56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288–291, 1991.

    Google Scholar 

  9. Hill BT, Whelan RDH, Shelland SH, et al.: Differential cytotoxic effects of Taxotere in a range of mammalian tumour cell lines in vitro. Ann Oncol 3:120, 1992.

    Google Scholar 

  10. Riou JF, Naudin, A, Lavelle F: Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187:164–170, 1992.

    Google Scholar 

  11. Bissery MC, Guenard D, Gueritte-Voegelein F, et al.: Experimental antitumor activity of Taxotere (RP56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845–4852, 1991.

    Google Scholar 

  12. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004–1014, 1995.

    Google Scholar 

  13. Huizing MT, Misser VHS, Pieter RC, Huinink WW, Veehof CHN, Vermorken JB, Pinedo HM, Beijnen JH: Taxanes: a new class of antitumor agents. Cancer Investigations 13:381–404, 1995.

    Google Scholar 

  14. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643–2655, 1955.

    Google Scholar 

  15. Jordan MA, Toso RJ, Thrower D, Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90:9552–9556, 1993.

    Google Scholar 

  16. Diaz JF, Andreu JM: Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 32:2747–2755, 1993.

    Google Scholar 

  17. Gueritte-Voegelein F, Guenard D, Lavelle F, et al.: Relationship between the structure of taxol analogues and their antimitotic activity. J Med Chem 34:992–998, 1991.

    Google Scholar 

  18. Parness J, Horwitz SB: Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479–487, 1981.

    Google Scholar 

  19. Mandredi JJ, Parness J, Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94:688–696, 1982.

    Google Scholar 

  20. Schiff PB, Horwitz SB: Taxol assembles tubulin in the absence of exogenous guanosine 5′ triphosphate or microtubule-associated proteins. Biochemistry 20:3247–3252, 1981.

    Google Scholar 

  21. Rao S, Horwitz SB, Ringel I: Direct photoaffinity labeling of tubulin with taxol. J Natl Cancer Inst 84:785–788, 1992.

    Google Scholar 

  22. Fromes Y, Gounon P, Bissery MC, et al.: Differential effects of Taxol and Taxotere (RP56976, NSC 628503) on tau and MAP2 containing microtubules. Proc Am Assoc Cancer Res 33:511, 1992 (abstract 3055).

    Google Scholar 

  23. Tishler RB, Schiff PB, Geard CR, Hall EJ: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613–617, 1992.

    Google Scholar 

  24. Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495–3497, 1992.

    Google Scholar 

  25. Choy H, Rodriguez F, Wilcox B, et al.: Radiation sensitizing effects of Taxotere (RP56976). Proc Am Assoc Cancer Res 33:500, 1992 (abstract 2991).

    Google Scholar 

  26. Choy H, Akerley W, Safran H, et al.: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12:2682–2686, 1994.

    Google Scholar 

  27. Cabral F, Wible L, Brenner S, Brinkley BR: Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 97:30–39, 1983.

    Google Scholar 

  28. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP: Taxol mechanisms of action and resistance. Monogr Natl Canc Inst 15:55–61, 1993.

    Google Scholar 

  29. Gupta RS: Taxol resistant mutants of Chinese hamsters ovary cells: genetic biochemical and cross-resistant studies. J Cell Physid 114:137–144, 1983.

    Google Scholar 

  30. Roy SN, Horwitz SB: A phosphoglycoprotein associated with Taxol resistance in J7742 cells. Cancer Res 45:3856–3863, 1985.

    Google Scholar 

  31. Rowinsky EK, Eisenhouer EA, Chaudhry V, Arbuck SA, Donehower RC: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:Suppl 3:1–15, 1993.

    Google Scholar 

  32. Eisenhouer EA, Ten Bokkel Huinick WW, Swenerton K, et al.: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus low-dose and long versus short infusion. J Clin Oncol 12:654–666, 1994.

    Google Scholar 

  33. Huizing MT, Keuing ACF, Rosing H, et al.: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127–2135, 1993.

    Google Scholar 

  34. Pazdur R, Newman RA, Newman BM, et al.: Phase I trial of Taxotere: five-day schedule. J Natl. Cancer Inst 84:1781–1788, 1992.

    Google Scholar 

  35. Extra JM, Rousseau F, Bruno R, et al.: Phase I and pharmacokinetic study of Taxotere (RP56976, NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037–1042, 1993.

    Google Scholar 

  36. Wanders J, Schrijvers D, Bruntsch U, et al.: The EORTC-ECTG experience with acute hypersensitivity reactions (HSR) in Taxotere studies. Proc Am Soc Clin Oncol 12:94, 1993 (abstract 1994).

    Google Scholar 

  37. Irwin B, Burris H, Kuhn J, et al.: Phase I trial of a 2 and 3 hour infusion of Taxotere. Proc Am Soc Clin Oncol 12:347, 1993.

    Google Scholar 

  38. Oulid-Aissa D, Behar A, Spielmann M, et al.: Management of fluid retention syndrome in patients treated with Taxotere (Docetaxel): effect of premedication. Proc Am Soc Clin Oncol 13:465, 1994 (abstract 1614).

    Google Scholar 

  39. Tomiak E, Piccart MJ, Kerger J, et al.: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12:1458–1467, 1994.

    Google Scholar 

  40. Seibel N, Ames M, Ivy P, Krailo M, Reid J, Kent P, Reaman G: Phase I and pharmacokinetic study of paclitaxel in refractory leukemia: A Childrens Cancer Group Study. Proc Am Soc Clin Oncol 13:324, 1994.

    Google Scholar 

  41. Hurwitz C, Relling M, Weitman SD, Ravindranath Y, Vietta TJ, Strother DR, Ragab AH, Pratt CB: Phase I trial of paclitaxel in children with refractory solid tumors: A Pediatric Oncology Group Study. J Clin Oncol 11:2324–2329, 1993.

    Google Scholar 

  42. Donfrancesco A, Deb G, Sio L, Habetswallner D, Helson L: Phase I trial of a Q4d Taxol regimen in pediatric patients with recurrent solid tumors. Proc Am Soc Clin Oncol 13:426, 1994 (abstract 1463).

    Google Scholar 

  43. Blaney S, Seibel N, O'Brien M, Mosher R, Reaman G, Poplack D, Balls F: Phase I study of Taxotere in pediatric patients. Proc Am Assoc Cancer Res 35:211, 1994 (abstract 1259).

    Google Scholar 

  44. Rowinsky EK, Burke PJ, Karp JE, Tucker RA, Ettengli D, Donehower RC: Phase I and pharmacodynamic study of Taxol in refractory acute leukemia. Cancer Res 49:4640–4647, 1989.

    Google Scholar 

  45. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV: Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12:532–538, 1994.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, D.C., USA

    Nita L. Seibel & Gregory H. Reaman

  2. the New Agents Committee of the Children's Cancer Group, Arcadia, CA, USA

    Nita L. Seibel & Gregory H. Reaman

  3. Department of Hematology/Oncology, Children's National Medical Center, 111 Michigan Avenue, N.W., 20010, Washington, DC, USA

    Nita L. Seibel & Gregory H. Reaman

Authors
  1. Nita L. Seibel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory H. Reaman
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for offprints: Nita L. Seibel, Department of Hematology/Oncology. Children's National Medical Center, 111 Michigan Avenue, N.W., Washington, DC 20010, USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seibel, N.L., Reaman, G.H. New microtubular agents in pediatric oncology. Invest New Drugs 14, 49–54 (1996). https://doi.org/10.1007/BF00173682

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00173682

Key words

Search

Navigation